[18F] 3-deoxy-3′-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-d-glucose positron emission tomography in the workup of suspicious central focal lesions?  by Halter, G. et al.
[18F] 3-deoxy-3'-fluorothymidine positron emission
tomography: Alternative or diagnostic adjunct to 2-[18F]-
fluoro-2-deoxy-D-glucose positron emission tomography in
the workup of suspicious central focal lesions?
G. Halter, MDa
A. K. Buck, MDb
H. Schirrmeister, MDb
I. Wurzigera
F. Liewald, MDa
G. Glatting, MDb
B. Neumaier, MDb
L. Sunder-Plassmann, MDa
S. N. Reske, MDb
M. Hetzel, MDc
Dr Halter
Background: 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomog-
raphy has been established as a standard diagnostic imaging method in the
preoperative workup of suspicious pulmonary focal lesions, showing a sensi-
tivity of more than 90% and a specificity of about 80%. Determination of
malignant pulmonary lesions with FDG positron emission tomography depends
on the assessment of glucose metabolism. However, false-positive findings can
occur in inflammatory processes, such as sarcoidosis or pneumonia. The thymi-
dine analogue 3-deoxy-3[18F]-fluorothymidine (FLT) is a new positron emission
tomography tracer that more specifically targets proliferative activity of malig-
nant lesions. The objective of this study was to determine whether FLT positron
emission tomography, in comparison with FDG positron emission tomography,
provides additional information in the preoperative workup of central pulmonary
focal lesions.
Methods: In this prospective study FLT and FDG positron emission tomography
examinations were performed as a part of the preoperative workup in 20 patients
with histologically confirmed bronchial carcinoma, 7 patients with benign lesions,
and 1 patient with an atypical carcinoid. Results were compared with final patho-
logic findings.
Results: For staging of the primary tumor, FLT positron emission tomography
revealed a sensitivity of 86% and a specificity of 100% compared with a sensitivity
of 95% and a specificity of 73% for FDG positron emission tomography. For N
staging, the sensitivity of FLT positron emission tomography was 57% and the
specificity was 100%, and for FDG positron emission tomography, the sensitivity
was 86% and the specificity was 100%, respectively.
Conclusions: Our preliminary findings indicate specific FLT uptake in malignant
lesions. The number of false-positive findings in FDG positron emission tomogra-
phy might be reduced with FLT positron emission tomography. Therefore positron
emission tomography imaging with FLT represents a useful supplement to FDG in
assessing the malignancy of central pulmonary focal lesions.
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Exact preoperative staging in patients withbronchial carcinoma is of crucial importancein determining appropriate therapeutic man-agement, especially when central focal le-sions are present. The potential role of2-[18F]-fluoro-2-deoxy-D-glucose positron
emission tomography (FDG-PET) in the diagnostic workup
of bronchial carcinoma has been investigated in numerous
studies beginning in the 1990’s. Determination of malignant
lesions with FDG-PET is based on glucose metabolism.
This also explains the lack of specificity because FDG-PET
shows increased activity in inflammatory processes, sar-
coidosis, or muscle activity.1-14
Shields and coworkers15,16 have developed the new PET
tracer 3-deoxy-3[18F]-fluorothymidine (FLT) for noninva-
sive detection of tumor proliferation.
A study by Rasey and coworkers17 using cultured A549
human lung carcinoma cells showed that FLT uptake cor-
related positively with cell growth and thymidine kinase 1
activity in the cytosol. In a first clinical trial, Buck and
associates18 demonstrated specific FLT uptake in malignant
pulmonary nodules in a series of 30 patients with unclear
pulmonary nodules. None of 8 benign lesions demonstrated
visible FLT uptake.
The objective of the present study was to investigate the
diagnostic accuracy of FLT-PET and whether the strategy
of specific imaging of proliferation can provide additional
information during the preoperative diagnostic workup.
Patients and Methods
In this prospective study 28 patients (21 men and 7 women) were
included (mean age, 63.4 years; range, 41-78 years). Only those
patients with findings of a central focal lesion on spiral computed
tomography (CT) were included in this study.
Patient Selection
In this prospective study FLT-PET was performed as part of the
preoperative workup in 20 patients with histologically confirmed
bronchial carcinoma, 7 patients with benign lesions, and 1 patient
with atypical carcinoid. For staging, patients also underwent FDG-
PET, CT scanning of the thorax, bronchoscopy with biopsy for
confirmation of the diagnosis, and upper abdominal ultrasonogra-
phy and whole-body bone scanning for detection of possible
distant metastases. Patients in whom the findings on CT, FDG-
PET, or both were consistent with stage N3 disease also underwent
diagnostic mediastinoscopy. Depending on the results of staging,
patients then underwent either chemotherapy or surgical manage-
ment. Staging was conducted in accordance with internationally
accepted staging guidelines. Surgical therapy with curative inten-
tion was performed in patients staged at International Union
Against Cancer stages I to IIIa. Mediastinal lymph node dissection
was performed according to the mapping scheme published by
Naruke and coworkers.19 The study was approved by our institu-
tional ethics commission, and all patients provided informed writ-
ten consent.
Synthesis of [18F]FLT
The detailed protocol of the synthesis of FLT was described
elsewhere.18,20 Briefly, benzoyl-protected anhydrothymidine was
used for FLT synthesis. Radiosynthesis was carried out in a PET
tracer synthesizer from a nuclear interface. After nucleophilic
introduction of [18F] fluoride accompanied by anhydro-ring open-
ing, deprotection of the benzylated intermediate was performed by
using 1% NaOH solution. [18F]FLT was purified by means of
preparative high-performance liquid chromatography.
Positron Emission Tomography
Both PET examinations were performed on consecutive days
within 2 weeks before resective surgery or core biopsy. PET was
performed with a high-resolution full-ring scanner (ECAT Exact
or ECAT HR, Siemens/CTI), which produces 47 or 63 contig-
uous slices per bed position. The axial field of view is 15.5 cm per
bed position. Five bed positions were measured in each patient,
covering a total field of view of 77.5 cm. The emission scan
included the thorax and abdomen in all patients. Patients fasted for
at least 6 hours before undergoing PET. Static emission scans were
performed 45 minutes after injection of 265 to 370 MBq of
[18F]FLT (mean, 334 MBq) and 345 to 550 MBq of [18F]FDG
(mean, 391 MBq), respectively. The acquisition time was 8 min-
utes per bed position. Three-minute transmission scans with a
germanium-68/gallium-68 ring source were performed for attenu-
ation correction after tracer application. Images were reconstructed
by using an iterative reconstruction algorithm described by
Schmidlin.21
All images were evaluated by 2 experienced nuclear medicine
physicians. For calculation of standardized uptake value, circular
regions of interest were drawn containing the area with focally
increased pulmonary FLT and FDG uptake.
Analysis of Data
The results of thorax CT scanning, FDG-PET, and FLT-PET were
compared with histologic findings, with subsequent determination
of the specificity (TN/[TN FP]), sensitivity (TP/[TP FN]) and
accuracy ([TP  TN]/[TP  TN  FP  FN]; TN  true
negative, TP  true positive, FP  false positive, and FN  false
negative).
Results
Surgical resection was performed within a time interval of
14 days in 22 patients. In the remaining patients diagnostic
staging and histologic confirmation of malignancy was per-
formed by means of mediastinoscopy, bronchoscopy, or
both.
Twenty-one patients had malignant lesions, and 7 pa-
tients had benign lesions. Lesions included 5 nondifferen-
tiated non–small cell bronchial carcinomas (Figure 1), 5
adenocarcinomas, 2 large cell bronchial carcinomas, 7 squa-
mous cell carcinomas, 1 small cell bronchial carcinoma, 1
atypical carcinoid, 1 lipoma with inflammatory margin, 1
case of tuberculosis (Figure 2), 1 bronchopulmonary chon-
droma, 1 instance of an anthracotic lymph node, 1 choles-
terol granuloma, and 2 cases of chronic, nonspecific bron-
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chitis (Table 1). Twelve patients with malignant tumors had
involvement of the lymph nodes.
Imaging of the Primary Tumor With FLT-PET and
FDG-PET
FLT-PET showed visible tracer uptake in 18 of 21 malig-
nant primary tumors. Therefore SUV values for FLT were
not calculated in the 3 negative lesions.
Mean [18F]FLT uptake in all patients was 2.0 (median,
1.7; SD, 2.1; range, negative to 5.6). In patients with bron-
chial carcinomas, mean FLT uptake was 2.9 (median, 3.0;
SD, 3.1; range, negative to 10.4). FLT-PET results were
false-negative in patient 7 with a highly differentiated ade-
nocarcinoma and in patient 11 with a histologically con-
firmed carcinoma in situ (non–small cell bronchial carci-
noma). A third malignant primary tumor (patient 28)
representing an atypical carcinoid also exhibited no visible
FLT uptake. False-positive findings were not returned in all
patients with benign lesions. This results in an overall
sensitivity of 86%, a specificity of 100%, and an accuracy of
90% for staging of the primary tumor.
Twenty of 21 malignant lesions exhibited focal accumu-
lation of FDG, resulting in a sensitivity of 95% for deter-
mination of the malignant primary tumor. Mean FDG up-
take in all lesions was 3.9 (median, 3.0; SD, 4.6; range,
negative to 10.6). In the malignant lesions mean FDG
uptake was 6.9 (median, 5.9; SD, 7.2; range, negative to
22.7). FDG-PET returned false-negative findings in patient
11 with a carcinoma in situ that were also negative on
FLT-PET. Of 7 patients with benign lesions, 2 exhibited
tumoral FDG uptake (Figure 3).
Lymph Node Status
FLT-PET staging results with regard to patient lymph node
status were true negative in 16 patients, false negative in 5
patients, and true positive in 7 patients. Thus the sensitivity
of FLT-PET for detecting malignant lymph nodes was 57%,
with a specificity of 100% and an accuracy of 82%. In
comparison, findings of FDG-PET were true positive in 10
patients, true negative in 16 patients, and false negative in 2
patients. On the basis of these findings, the sensitivity of
FDG-PET for determination of patients’ lymph node status
is 86%, with a specificity of 100% and an accuracy of 93%
(Figure 4).
Discussion
In a meta-analysis of 15 studies including a total of 1144
patients, determination of the malignant primary tumor with
FDG-PET was associated with a sensitivity of 96% and a
specificity of 80%. The performance of FDG-PET in N
staging (20 studies, 1292 patients; sensitivity, 88%; speci-
ficity, 92%; accuracy, 91%) was superior to that of CT (19
studies, 1268 patients; sensitivity, 65%; specificity, 76%;
accuracy, 73%).6,22-24
Numerous studies have investigated the role of FDG-
PET in the diagnosis of central bronchial carcinoma. In a
meta-analysis published by Hellwig and colleagues,6 a sen-
sitivity of 96% and a specificity of 80% was described for
functional imaging with PET. FDG, however, is not a se-
lective tracer. An increased uptake is observed in both
malignant tissue and inflammatory lesions.7,25 In the search
for a more selective tracer for PET imaging identifying
cellular proliferation, Shields and coworkers16 reported ini-
tial findings regarding the use of the thymidine analog FLT
in a pilot study. FLT was first evaluated as a chemothera-
peutic agent for the treatment of leukemia.26 Researchers
soon discovered its exceptional anti-HIV activity.27 Toxic-
ity observed during phase II clinical trials with FLT deterred
investigation of the drug administered at pharmacologic
doses.28 The successful labeling of FLT with 18F led to a
novel proposal to use [18F]FLT as a radiopharmaceutical for
monitoring HIV infection.29,30 Although this application
was never pursued in animal models, the concept formed the
basis for imaging cell proliferation in tumors.
In the present study 28 patients with unclear central focal
lesions were included, and PET imaging with FLT was
performed in all patients. For preoperative staging, all pa-
tients additionally underwent FDG-PET. With regard to
detection of the primary tumor, FDG-PET showed a sensi-
tivity of 95%, which, despite the small number of patients,
agrees with sensitivity values reported in the literature
(88%-97%).6,22-24 FDG-PET also returned false-positive re-
sults in 2 of 7 patients with inflammatory lesions. The
Figure 1. A, FLT-PET (transaxial section) of patient 2 with a
non–small cell bronchial carcinoma in the left upper lobe (T2 N0
M0). Tumoral FLT uptake indicates moderate proliferative activity.
B, Corresponding transaxial section of FDG-PET with intense
tracer uptake. C, Coronal section of FLT-PET demonstrating up-
take of the primary tumor and physiologic uptake in the prolifer-
ating bone marrow of the spine, pelvis, ribs, and scapula. Accu-
mulation in the liver is related to FLT glucoronization. D,
Corresponding FDG-PET section, physiologic accumulation in the
bladder caused by renal excretion of FDG.
Halter et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 4 1095
G
TS
decreased specificity of FDG-PET is also well documented
in the literature.4,6,7 However, there were no false-positive
findings reported for FLT-PET, yielding a specificity of
100%. False-negative FLT-PET findings were returned in 3
patients. Therefore FLT-PET was less sensitive when com-
pared with FDG in our series. The histologically confirmed
diagnosis in one of these patients was carcinoma in situ,
whereas a second patient exhibited a highly differentiated
adenocarcinoma, and a third exhibited an atypical carcinoid.
These findings correspond to data published by Buck and
associates18 describing less favorable results for FLT-PET
in patients with well-differentiated tumors. The carcinoma
Figure 2. A, FDG-PET of patient 22 with active pulmonary tuberculosis and additional spondylodiscitis. Intense FDG
uptake in a central pulmonary lesion on the right side and additional uptake in multiple mediastinal lymph nodes
on both sides is shown. B, Corresponding FLT-PET section: no tracer uptake indicates no increased tumoral
proliferation. C, Coronal section of FDG-PET demonstrating high tracer uptake in the lesions and physiologic renal
excretion of the tracer. D, Corresponding section of FLT-PET demonstrating only physiologic tracer uptake. E,
Coronal section of FDG-PET with longitudinal tracer uptake in the thoracic intervertebral disc 5/6 indicating
tuberculosis related discitis. F, Corresponding FLT-PET scan shows no tracer uptake in the inflammatory process
and in the neighboring vertebrae 5 and 6.
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in situ was also missed with FDG-PET, which is probably
related to partial volume effects.
With regard to the patients’ lymph node status, FLT-PET
again showed a high specificity of 100% and a decreased
sensitivity of 57%. True-positive findings on FLT-PET
were returned in only 7 of 12 patients, which, even in this
small patient collective, would suggest that FLT-PET is less
sensitive for lymph node staging. For N staging, FDG-PET
TABLE 1. Characteristics of 28 patients with central focal lesions, comparison of FLT-PET and FDG-PET findings, and
corresponding histopathologic diagnosis
Patient no. Histopathology TNM FLT-PT FLT-N FDG-PT FDG-N
1 Adenocarcinoma T1 N3 TP FN TP TP
2 NSCLC T2 N0 TP TN TP TN
3 NSCLC T2 N2 TP FN TP FN
4 NSCLC T3 N3 TP TP TP TP
5 NSCLC T2 N3 TP TP TP TP
6 LCC T2 N0 TP TN TP TN
7 SCC T4 N1 TP TP TP TP
8 Adenocarcinoma T2 N1 FN FN TP TP
9 SSC T3 N0 TP TN TP TN
10 SCC T4 N2 TP TP TP TP
11 SSC, carcinoma in situ T1 N0 FN TN FN TN
12 LCC T2 N2 TP TP TP TP
13 Adenocarcinoma T4 N1 TP FN TP FN
14 Adenocarcinoma T1 N2 TP FN TP TP
15 Adenocarcinoma T2 N0 TP TN TP TN
16 SCC T3 N1 TP TP TP TP
17 SCC T2 N1 TP TP TP TP
18 NSCLC T2 N0 TP TN TP TN
19 SCC T1 N1 TP TP TP TP
20 SCC T2 N2 TP FN TP TP
21 TBC – TN TN FP TN
22 Nonspecific bronchitis – TN TN TN TN
23 Atypical lipoma with
inflammatory change
– TN TN TN TN
24 Nonspecific bronchitis – TN TN FP TN
25 Bronchopulmonary
chondroma
– TN TN TN TN
26 Anthrakotic LN – TN TN TN TN
27 Cholesterol granuloma – TN TN TN TN
28 Atypical carcinoid – FN TN TP TN
FLT, [18F] 3-deoxy-3'-fluorothymidine; PT, primary tumor; N, lymph node status; FDG, [18F]-fluoro-2-deoxy-D-glucose; TP, true positive; FN, false negative;
NSCLC, non–small cell bronchial carcinoma; TN, true negative; LCC, large-cell bronchial carcinoma; SCC, small-cell bronchial carcinoma; SSC, squamous
cell carcinoma; TBC, tuberculosis; FP, false positive; LN, lymph node.
Figure 3. PET findings: malignant and benign primary tumors.
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exhibited a sensitivity of 86% and a specificity of 100%
(Figure 3).
Considering the data as a whole, we see a decreased
sensitivity of FLT-PET in terms of detection of well-differ-
entiated tumors. Corresponding findings for primary tumors
have also been reported by Buck and associates,18 who
calculated a correlation coefficient of 0.9 for tumoral FLT
uptake and the proliferative activity measured by Ki-67
immunohistochemistry. For FDG-PET, Veselle and col-
leagues13 and Higashi and coworkers25 reported a correla-
tion coefficient of 0.7 for tumoral FDG uptake and prolif-
erative activity. This suggests that FDG uptake is not
dependent solely on tumor proliferation leading to an in-
creased tumoral tracer uptake.
For lymph node staging, it was found that lymph node
metastases of poorly differentiated primary tumors were
also frequently missed (false-negative findings in 6 of 13
patients). Because detailed histopathologic examination of
lymph nodes has not been performed, precise information
about the origin of false-negative findings cannot be given.
However, small lesions might be missed with PET because
of low tracer uptake, motion artifacts, or partial volume
effects. Because the glucose analog FDG additionally accu-
mulates in inflammatory cells rather than tumor cells alone,
a higher sensitivity of FDG-PET seems feasible. This issue
deserves to be investigated in further studies to determine
both the lymph node proliferation rate and the detection
rates of FLT-PET.
In conclusion, FLT-PET is potentially a useful adjunct to
FDG-PET in assessing the malignancy of central focal
lesions. Its strength lies in identifying those instances in
which false-positive FDG-PET findings are related to in-
flammatory processes. Another potential role of the method
lies in its use for monitoring therapeutic response. For
primary staging, FLT-PET does not appear suitable as a
substitute for FDG-PET because of its weakness in detect-
ing well-differentiated tumors and in lymph node staging.
Further studies with larger numbers of patients are required
to definitively resolve these questions.
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